Control Bionics Ltd. · ASX:CBL
Control Bionics — Bell Potter Healthcare Conference 2026
7 slides from Control Bionics's conference presentation, Nov 18, 2026
Slide 1: Empowerment through proven neurotechnology
rsonal use only BELL POTTER HEALTHCARE CONFERENCE 2026 Empowerment through proven neurotechnology Business update, growth strategy and near-term catalysts 18 November 2026 | ASX: CBL Jeremy Steele, CEO & Managing Director · jsteele@controlbionics.com
Slide 2: Important Notice: Disclaimer
IMPORTANT NOTICE Disclaimer rsonal use only This presentation is intended to provide a general outline only and is not intended to be a definitive statement on the subject matter covered in it. The information in this presentation, whether written or verbal, has been prepared without taking into acc
Slide 3: Control Bionics at a Glance: One neural-signal platform, three pillars
CONTROL BIONICS AT A GLANCE One neural-signal platform. Three commercial pillars. Non-invasive surface EMG (sEMG) that reads the faintest muscle signal, refined over 25 years with people who can barely move. rsonal use only NeuroNode NeuroStrip Live sEMG data PILLAR 1 · REVENUE ENGINE PILLAR 2 · GRO
Slide 4: Assistive Communication: Funded devices, sold through the largest AAC distributors
PILLAR 1 · ASSISTIVE COMMUNICATION Funded devices, sold through the largest AAC distributors Growth scales with the number of partner consultants we train, not with Control Bionics sales headcount. rsonal use only US$1B+ US$4,300 80%+ ~1 quarter global AAC market, growing >10% a NeuroNode funded und
Slide 5: NeuroTech Solutions: Leading sport and rehab organisations use NeuroStrip
PILLAR 2 · NEUROTECH SOLUTIONS Leading sport and rehab organisations use NeuroStrip Objective muscle data for return-to-play and rehabilitation decisions, in a >$4.2B addressable market (management estimate). rsonal use only NEUROSTRIP 4g 4 channels with electrode patch sEMG, plus motion data and vi
Slide 6: Trial customers are becoming long-term paying customers
PILLAR 2 · FROM TRIAL TO PAYING CUSTOMER Trial customers are becoming long-term paying customers A paying customer buys NeuroStrip hardware, a NeuroStrip.IQ subscription and patches: $5k to $50k a year per organisation. rsonal use only organisations engaged ~80 in AU/NZ, the US and Europe ~30 in liv
Slide 7: Six catalysts we will report against in FY27
WHY CONTROL BIONICS · NEAR-TERM CATALYSTS Six catalysts we will report against in FY27 Each ties to a milestone set out at the AGM on 13 October 2026. rsonal use only NeuroStrip conversions WHY CONTROL BIONICS 1 Dec quarter First trial-cohort conversion outcomes reported Proven and protected 25 year
Control Bionics — Bell Potter Healthcare Conference 2026 on 6ix